HCAT Stock Overview
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations.
Health Catalyst Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$15.40|
|52 Week High||US$59.50|
|52 Week Low||US$11.25|
|1 Month Change||9.77%|
|3 Month Change||-44.26%|
|1 Year Change||-72.83%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-60.68%|
Recent News & Updates
|HCAT||US Healthcare Services||US Market|
Return vs Industry: HCAT underperformed the US Healthcare Services industry which returned -40.4% over the past year.
Return vs Market: HCAT underperformed the US Market which returned -21.7% over the past year.
|HCAT Average Weekly Movement||12.5%|
|Healthcare Services Industry Average Movement||12.7%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: HCAT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: HCAT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017.
Health Catalyst Fundamentals Summary
|HCAT fundamental statistics|
Is HCAT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HCAT income statement (TTM)|
|Cost of Revenue||US$130.50m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.72|
|Net Profit Margin||-57.95%|
How did HCAT perform over the long term?See historical performance and comparison
Is HCAT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HCAT?
Other financial metrics that can be useful for relative valuation.
|What is HCAT's n/a Ratio?|
Price to Sales Ratio vs Peers
How does HCAT's PS Ratio compare to its peers?
|HCAT PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
SLP Simulations Plus
NXGN NextGen Healthcare
CNVY Convey Health Solutions Holdings
HCAT Health Catalyst
Price-To-Sales vs Peers: HCAT is good value based on its Price-To-Sales Ratio (3.3x) compared to the peer average (7.5x).
Price to Earnings Ratio vs Industry
How does HCAT's PE Ratio compare vs other companies in the US Healthcare Services Industry?
Price-To-Sales vs Industry: HCAT is expensive based on its Price-To-Sales Ratio (3.3x) compared to the US Healthcare Services industry average (3.1x)
Price to Sales Ratio vs Fair Ratio
What is HCAT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||3.3x|
|Fair PS Ratio||3x|
Price-To-Sales vs Fair Ratio: HCAT is expensive based on its Price-To-Sales Ratio (3.3x) compared to the estimated Fair Price-To-Sales Ratio (3x).
Share Price vs Fair Value
What is the Fair Price of HCAT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate HCAT's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate HCAT's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HCAT's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Health Catalyst forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HCAT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HCAT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HCAT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HCAT's revenue (16% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: HCAT's revenue (16% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HCAT is forecast to be unprofitable in 3 years.
Discover growth companies
How has Health Catalyst performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HCAT is currently unprofitable.
Growing Profit Margin: HCAT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HCAT is unprofitable, but has reduced losses over the past 5 years at a rate of 4.1% per year.
Accelerating Growth: Unable to compare HCAT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HCAT is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (3.7%).
Return on Equity
High ROE: HCAT has a negative Return on Equity (-30.63%), as it is currently unprofitable.
Discover strong past performing companies
How is Health Catalyst's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: HCAT's short term assets ($482.5M) exceed its short term liabilities ($92.7M).
Long Term Liabilities: HCAT's short term assets ($482.5M) exceed its long term liabilities ($251.4M).
Debt to Equity History and Analysis
Debt Level: HCAT has more cash than its total debt.
Reducing Debt: Insufficient data to determine if HCAT's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HCAT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: HCAT has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 3.2% each year
Discover healthy companies
What is Health Catalyst current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HCAT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HCAT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HCAT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HCAT's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as HCAT has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dan Burton (47 yo)
Mr. Daniel D. Burton, also known as Dan, has been the Chief Executive Officer of Health Catalyst, Inc. since October 2012 and has been its Director since September 2011. Mr. Burton has strategy and leaders...
CEO Compensation Analysis
Compensation vs Market: Dan's total compensation ($USD5.96M) is above average for companies of similar size in the US market ($USD4.03M).
Compensation vs Earnings: Dan's compensation has increased whilst the company is unprofitable.
Experienced Management: HCAT's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Experienced Board: HCAT's board of directors are considered experienced (5.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.7%.
Health Catalyst, Inc.'s employee growth, exchange listings and data sources
- Name: Health Catalyst, Inc.
- Ticker: HCAT
- Exchange: NasdaqGS
- Founded: 2008
- Industry: Health Care Technology
- Sector: Healthcare
- Implied Market Cap: US$834.450m
- Shares outstanding: 54.19m
- Website: https://www.healthcatalyst.com
Number of Employees
- Health Catalyst, Inc.
- 10897 South River Front Parkway
- Suite 300
- South Jordan
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/01 00:00|
|End of Day Share Price||2022/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.